• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Vascular Dysfunction - Pipeline Review, Q3 2011 - Product Image

Vascular Dysfunction - Pipeline Review, Q3 2011

  • Published: July 2011
  • 29 pages
  • Global Markets Direct

Vascular Dysfunction - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Vascular Dysfunction - Pipeline Review, Q3 2011', provides an overview of the Vascular Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Vascular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vascular Dysfunction. 'Vascular Dysfunction - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vascular Dysfunction.
- A review of the Vascular Dysfunction products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vascular Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Vascular Dysfunction
Vascular Dysfunction Therapeutics under Development by Companies
Vascular Dysfunction Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Vascular Dysfunction Therapeutics - Products under Development by Companies
Vascular Dysfunction Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Vascular Dysfunction Therapeutics Development
Takeda Pharmaceutical Company Limited
BioMarin Pharmaceutical Inc.
Novogen Limited
Vascular Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
6R-BH4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trans NV-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fasudil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vascular Dysfunction Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Vascular Dysfunction, Q3 2011
Products under Development for Vascular Dysfunction – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Takeda Pharmaceutical Company Limited, 2011
BioMarin Pharmaceutical Inc., 2011
Novogen Limited, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Vascular Dysfunction Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Vascular Dysfunction, Q3 2011
Products under Development for Vascular Dysfunction – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos